AB&B BIO-TECH-B (02627): Adsorbed Tetanus Toxoid Vaccine Receives IND Approval from China's Center for Drug Evaluation

AB&B BIO-TECH-B (02627) announced that the Center for Drug Evaluation of the National Medical Products Administration (China's CDE) approved the Group's self-developed investigational new drug (IND) application for its adsorbed tetanus toxoid vaccine (adsorbed tetanus vaccine) candidate product on November 12, 2026. Tetanus is an acute specific infection caused by spores of Clostridium tetani entering the body through wounds, and can be very dangerous or even fatal. Spores are ubiquitous in the environment, particularly in soil, ash, animal and human feces, and on surfaces such as skin and tools including rusty nails, needles and barbed wire. Tetanus prevention relies mainly on proper wound management and immunization: primary prevention through active immunization involves vaccination with vaccines containing tetanus toxoid to produce long-term immunity in the body; while secondary prevention, i.e. passive immunization, uses immediate immune effectors such as tetanus antitoxin (TAT) or immunoglobulin for acute cases. The Group's investigational adsorbed tetanus vaccine is designed to induce the body to produce protective antitoxin antibodies through immunization. The Board believes that this IND application approval by China's CDE marks important progress in the Group's research and development in the traditional vaccine field and lays the foundation for the conduct of clinical studies of this candidate product.